As capsid development becomes a higher priority for AAV gene therapy innovators, a fundamental shift is underway: Development teams are relying less on common capsid library options and more on rationally designed and directed methods to generate novel capsids for specific indications.
Yet that shift has a clear impact on manufacturing, since novel capsids can’t be assumed to enjoy an automatic plug-and-play status with existing platform processes. Cell & Gene recently brought together an expert panel to hash through the implications that introducing novel capsids can have on everything from immunogenicity and analytical assays to machine learning and regulatory packages. The webinar was moderated by Viralgen Chief Commercial Officer Andy Holt and included insights from Jacob Smith of Viralgen, Laurence Jeanson-Leh and Sabrina Triffault of GenoSafe, and Daniel Lourenco and Jacob Staudhammer of Darkhorse Consulting.
View the webinar below to discover how the successful implementation of novel capsids may point the way to higher manufacturing efficiency and lower COGS.
